Drug Profile


Alternative Names: R 639; RO 67-0565; SPP 301

Latest Information Update: 26 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Speedel Pharmaceuticals
  • Class Cardiovascular therapies; Pyridines; Pyrimidines; Sulfonamides
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic nephropathies

Most Recent Events

  • 07 May 2009 No development reported - Phase-II for Diabetic nephropathies in European Union (PO)
  • 09 Jul 2008 Speedel has been acquired by Novartis
  • 19 Jun 2008 Preclinical pharmacodynamics data presented at the 18th European Society of Hypertension and the 22nd Scientific Meeting of the International Society of Hypertension (HYP-2008) ,,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top